Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Pollyea, Daniel A.
Jordan, Craig T.
Smith, Clayton A.
Gutman, Jonathan A.
Text and Data Mining valid from 2021-10-13
Version of Record valid from 2021-10-13
6 June 2021
6 September 2021
17 September 2021
13 October 2021
D.P. has received research funding and served as a consultant to Abbvie.